Non-Small Cell Lung Cancer

Ticiana Leal, MD, Winship Cancer Institutes, explains the importance of biomarker testing and multidisciplinary conversations while caring for patients with early-stage non–small cell lung cancer (NSCLC).

Study results show that a portable breath analysis device designed for early detection of non–small cell lung cancer may distinguish between patients with the disease and healthy individuals.

The approval came days before the FDA’s expected deadline and makes this the only PD-1 inhibitor approved for resectable non–small cell lung cancer (NSCLC) in the neoadjuvant and adjuvant settings.

In less than a month, from August 20 to September 19, amivantamab (Ami; Rybrevant, Johnson & Johnson) received 2 approvals from the FDA for use in non–small cell lung cancer (NSCLC).

On September 19, the FDA handed down its third amivantamab (Rybrevant; Johnson & Johnson) approval for 2024 in non–small cell lung cancer (NSCLC), giving the third-generation tyrosine kinase inhibitor its fourth approval overall.

The approval means an additional indication for osimertinib (Tagrisso; AstraZeneca) for adult patients who have unresectable stage III non–small cell lung cancer (NSCLC) with EGFR mutation.

The FDA approval of amivantamab-vmjw (Rybrevant) in combination with chemotherapy is the first targeted treatment to cut disease progression risk for EGFR-positive non–small cell lung cancer (NSCLC).

Here we conclude our discussion with David P. Carbone, MD, PhD, The Ohio State University, by addressing the importance of both advocacy for and education on biomarker testing in the lung cancer space.

Developers anticipate releasing full efficacy results from the phase 2 THIO-101 trial later this year.

This newest approval for amivantamab is the second approval in 6 months for the EGFR and MET bispecific antibody.

Measures of systemic inflammation used for the liver, including C-reactive protein-albumin ratio and modified Glasgow prognostic score, demonstrated prognostic value in non–small cell lung cancer (NSCLC).

In part 1 of our interview with David P. Carbone, MD, PhD, The Ohio State University, he addressed why it is important to conduct biomarker testing in both lung cancer overall and non–small cell lung cancer more specifically.

Patients with non-small cell lung cancer (NSCLC) can use lazertinib in combination with amivantamab as a first-line treatment.

The panel provides insights on enhancing outcomes for patients with metastatic non-small cell lung cancer without targetable driver mutations.

This investigation was conducted among older, frail patients, a population typically underrepresented in clinical trials.

The panel shares clinical practices for overcoming immunotherapy resistance in patients with non-small cell lung cancer.

A panel of experts on non-small cell lung cancer outline factors that impact how well patients respond to immunotherapy.

David P. Carbone, MD, PhD, director of the thoracic oncology center at The Ohio State University in Columbus, discusses the importance of biomarker testing in both lung cancer overall and non–small cell lung cancer specifically.

New therapies to treat EGFR-mutated non–small cell lung cancer (NSCLC) following EGFR tyrosine kinase inhibitors (TKIs) are needed to address EGFR TKI resistance after osimertinib.

Visceral pleural invasion of non–small cell lung cancer (NSCLC) was investigated in this analysis for its potential to predispose patients to worse survival outcomes and greater chances of disease recurrence.

Jason Porter, MD, provides concluding insights on the LAURA phase 3 trial, CHRYSALIS-2 study, TROPION-Lung05 trial, and CheckMate 9LA study, along with other notable findings from the ASCO 2024 conference.

Should the FDA require that new trial design proposals for perioperative regimens for resectable non–small cell lung cancer (NSCLC) include adequate within trial assessment?

Patients with unresectable stage III non–small cell lung cancer (NSCLC) who received atezolizumab before and after chemoradiation therapy (CRT) had both safe and effective results.

A key opinion leader examines the overall survival data from the CheckMate 9LA study, which evaluated nivolumab plus ipilimumab plus chemotherapy in metastatic non-small cell lung cancer patients, and explores how the long-term follow-up results inform treatment decisions in this setting.